18 results on '"Feng, W."'
Search Results
2. P1.24-13 Role of EVs-miR-200b-5p Mediating Tgf-β Signaling Pathway in Radiation Pneumonia
3. MA04.03 Osimertinib-induced Epigenetic and Transcriptional Reprogramming Drives a BRD4-POUF-PDGFRB-YAP-EMT Axis of Resistance in NSCLC
4. P1.28-02 EVs-miRNAs-Based Models in Predicting Radiosensitive Patients with Local Advanced-NSCLC Who Can Benefit from Adaptive Radiotherapy
5. EP.13B.15 Radiotherapy Combined with Immunotherapy in the Treatment of Brain Metastases from Small Cell Lung Cancer
6. P3.12C.02 MET Fusions in NSCLC: Prevalence, Oncogenicity, and Resistance Mechanism
7. P68.07 Long Non-Coding RNA linc00665 Inhibits CDKN1C Expression by Binding to EZH2 and Affects Cisplatin Sensitivity of NSCLC
8. P48.11 ctDNA Dynamic Detection Reveals the Advantages of EGFR Tyrosine Kinase Inhibitors Combined With Chemotherapy in NSCLC Patients
9. P20.02 To Evaluate the Efficacy and Optimal Timing of Postoperative Radiotherapy in Completely Resected stage IIIA(N2) Non-Small Cell Lung Cancer
10. P17.01 Adaptive Elastic-Net Nomogram Predicting Disease-Free Survival in Resected Stage IIIA (N2) Non–Small Cell Lung Cancer
11. P76.77 Combination of EGFR-TKIs with Chemotherapy versus EGFR-TKIs alone in EGFR-Mutant Advanced NSCLC with Concomitant Genetic Alterations
12. MA03.04 A Deep Learning Model to Predict Occult Lymphatic Metastasis in Clinical Stage I Non-Small Cell Lung Cancer Based on Chest CT
13. P3.08F.02 MRD Guiding Treatment after Aumolertinib Induction Therapy for EGFRm+ Stage III NSCLC in the MDT Diagnostic Model (APPROACH)
14. P2.16-04 Single-Port Video-Assisted Thoracoscopic Surgery Reduces Patient-Reported Symptom Burden in Patients Undergoing Lung Resection
15. P2.09-11 Genomic Profiling of Pulmonary Lymphoepithelioma-Like Carcinoma (PLELC)
16. MA 17.02 Clinical Impact of the Tumor Immune Microenvironment and Immunoscore in Completely Resected Stage IIIA(N2) Non-Small Cell Lung Cancer
17. MA 17.03 Prognostic Value of the New IASLC/ATS/ERS Lung Adenocarcinoma Classification in Completely Resected Stage IIIA(N2) NSCLC
18. OA09.04 ILLUMINATE: Efficacy and Safety of Durvalumab-Tremelimumab and Chemotherapy in EGFR Mutant NSCLC Following Progression on EGFR Inhibitors.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.